Skip to Main Content

Wilson J. Liao


Clinical center director, researcher of genetics and immunity

Dr. Wilson Liao specializes in caring for patients with psoriasis and other skin disorders that may respond to phototherapy (exposure to ultraviolet light).

Liao is interested in bringing cutting-edge research technologies into patient care in the clinic, a field called translational medicine. He is involved in a number of research studies on new therapies for psoriasis and skin cancer, and welcomes patient inquiries on study participation.

Liao earned his medical degree at Harvard Medical School. He completed both his residency and fellowship in dermatology at UCSF.

  • Education

    Harvard Medical School, 2003

  • Residencies

    UCSF, Dermatology, 2007

  • Fellowships

    UCSF, Dermatology, 2007

  • Board Certifications

    Dermatology, American Board of Dermatology

  • Academic Title


  • Languages


Let’s work together to cure skin diseases. If we can imagine it, we can achieve it.

Where I see patients (2)

    My reviews


    Overall Experience
    63 Ratings
    Explained things in a way that was easy to understand
    62 Ratings
    Did the doctor pay attention to your concerns
    63 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    60 Ratings
    Knew the important information about your medical history
    63 Ratings
    The provider showed respect for what you had to say
    62 Ratings
    The provider spent enough time with me
    62 Ratings

    Selected research

    Decorative Caduceus

    Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

    Patient eczema area and severity index (EASI) will be measured. It is a tool for measuring the amount and severity of eczema a patient has on his or her body, scale is 0-72, 0 means clear and 72 means severe eczema


    Decorative Caduceus

    Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

    Percentage change from pre-treatment baseline of CD4+ T effector cells expressing IL-4 at weeks 2, 4, 12 in dupilumab-treated patients.


    Decorative Caduceus

    Guselkumab Immunogenetics

    Mean change from baseline in percent of lesional CD4+ T effector cells producing IL-17